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Darkening and Eruptive Nevi During Treatment With Erlotinib
Stephen Hemperly, DO, Tanya Ermolovich, DO, and Nektarios Lountzis, MD
Lehigh Valley Health Network, Allentown, Pennsylvania

Case Presentation:

Discussion:

Patient: 70 year-old Caucasian male.
History of Present Illness: Our patient
developed eruptive nevi and darkening of his existing
nevi three months after beginning erlotinib for treatment
of non-small cell lung carcinoma. The patient’s prior
chemotherapeutic regimen was discontinued five weeks
before starting erlotinib. A complete cutaneous exam after
completion of these chemotherapeutic agents and prior
to initiation of erlotinib was unremarkable for abnormally
dark or eruptive nevi. Of note, the patient had not had
a melanoma diagnosed since 2006. However, since the
start of erlotinib the patient had ten biopsies performed on
clinically suspicious dark nevi, two of which were favored
to be melanoma in situ and one an atypical nevus.
Medical History/Surgical History: Nonsmall cell lung cancer (May 2012), invasive melanomas
x3, atypical nevi, hypertension, diabetes, diverticulitis,
gastroesophageal reflux disease, chronic obstructive
pulmonary disease, left lower lobectomy and lymph
node dissection (July 2012), pacemaker and defibrillator
placement, gastric bypass, appendectomy, cholecystectomy
Medications: Erlotinib (started May 2013),
lansoprazole, fosinopril, metformin, aspirin, simvastatin,
niacin, nifedipine, bisoprolol fumarate/hydrochlorothiazide,
furosemide
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Figure 1A: July 2010: Patient’s back before treatment with erlotinib (started May, 2013).
Figure 1B: Dec. 2013: Patient’s back demonstrating darkened and eruptive nevi during treatment with erlotinib (started May, 2013).
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Figure 2: Timeline and clinical photos demonstrating changes in nevi in relation to chemotherapeutic treatments.

Previous Lung Cancer Treatments:
Docetaxel, carboplatin, and pegfilgrastim (9/2012 11/2012), decadron and palonosetron (9/2012 - 4/2013),
pemetrexed (3/2013 - 4/2013)
Physical Examination: Numerous dark brown
to black macules on the trunk and bilateral extremities.
Scattered papules and pustules with generalized xerosis on
the trunk and extremities.
Studies: c-KIT immunostaining revealed a mild to
moderate increase in intensity in nevi and melanomas
post-darkening compared to similar pre-darkened lesions.
Biopsy: Advanced Dermatology Associates, LTD
(AD13-08457, 8/22/2013); Right posterior shoulder:
“Population of heavily pigmented, keratinocyte-sized
melanocytes in coalescing, ill-defined, junctional and
intraepidermal aggregates of varying morphology.
Additionally, there is a population of solitary melanocytes
scattered throughout the spinous zone.”
Advanced Dermatology Associates, LTD (AD13-12842,
12/12/2013); Right posterior shoulder: “Junctional nests of
plump spindled melanocytes varying in size and shape are
crowded throughout with focal coalescence.”

Erlotinib is a small molecule tyrosine kinase inhibitor that functions by blocking the
intracellular portion of the epidermal growth factor receptor (EGFR). This blockade
prevents tyrosine kinase phosphorylation and the activation of the mitogen-activated
protein kinase (MAPK) signaling pathway involved in cell growth and proliferation. EGFR
is found in the basal layer of the epidermis, sweat glands, and hair follicles, and is
overexpressed in some cancers. Erlotinib is indicated in the treatment of non-small cell
lung cancer and advanced stage pancreatic cancer. A number of cutaneous side effects
have been reported including an acneiform eruption (63%), xerosis (7.7%), pruritus (3.8%),
and paronychia (6%).
Eruptive nevi have been reported in one patient treated with erlotinib, and in seven
patients treated with sorafenib, a multikinase inhibitor that also affects the MAPK
pathway. Vemurafenib, a selective inhibitor of BRAF in the MAPK pathway, has been
reported to produce dysplastic nevi, melanomas, eruptive nevi, and darkening of existing
nevi. Changes in nevi were noted within a few months of initiating treatment with
these medications. The effects of vemurafenib have been ascribed to a paradoxical upregulation of MAPK, which has been well documented and demonstrated in vivo. Perhaps
erlotinib has a similar potential to paradoxically up-regulate MAPK or other enzymes in the
pathway, thus stimulating cellular proliferation and survival.
We decided to investigate c-KIT, a tyrosine kinsae receptor that activates the MAPK
pathway and is critical to the development and survival of melanocytes. Stimulation of
c-KIT tyrosine kinase can also induce melanocyte proliferation and pigment production/
melanogenesis. Activating mutations of c-KIT have been described in some cases of
melanoma. In our patient, c-KIT immunostaining revealed a mild to moderate increase
in intensity in nevi and melanomas post-darkening compared to similar pre-darkened
lesions. Increased expression of c-KIT, possibly reactive to downstream inhibition of the
MAPK pathway from erlotinib, could be implicated in our case of eruptive nevi.
To our knowledge, this is the first reported case of darkening of existing nevi, eruptive
nevi, and melanoma in situ during treatment with erlotinib. The timeline and clinical
similarities to previous reports of changes in nevi with other agents affecting the MAPK
pathway provide support for erlotinib as the causative agent in our patient. We therefore
suggest frequent full body cutaneous examinations to monitor for possible melanocytic
atypia or development of malignant melanoma.
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Figure 3A: December 2013: Clinical image of a melanoma in situ on the right posterior shoulder.
Figure 3B: H&E 20x December 2013: Right posterior shoulder: Melanoma in situ. “Junctional nests of plump spindled
melanocytes varying in size and shape are crowded throughout with focal coalescence.”
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Figure 4A: c-KIT 20x July 2010: Left nasal sidewall: Melanocytic nevus, compound. “c-KIT immunostaining of a nevus before
treatment with erlotinib demonstrating weak staining of the dermal melanocytes.”
Figure 4B: c-KIT 20x December 2013: Right lateral back: Melanocytic nevus, compound. “c-KIT immunostaining of a darkened
nevus during treatment with erlotinib demonstrating increased staining most appreciated in the dermal melanocytes.”
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